release tablet contains 40 mg of Pantoprazole GPO 40 mg

An Open Label, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Oral Dose, Crossover Bioequivalence Study of Pantoprazole GPO (40 mg) (Pantoprazole 40 mg Delayed-Release Tablets) of The Government Pharmaceutical Organization, Thailand with CONTROLOC (Pantoprazole 40 mg Gastro-Resistant Tablets) of Takeda GmbH, Germany, in Normal, Healthy, Adults Human Subjects under Fasting Conditions

An Open Label, Randomized, Two-Treatment, Four-Period, Two-Sequence, Single Oral Dose, Crossover, Fully Replicate Bioequivalence Study of Pantoprazole GPO (40 mg) (Pantoprazole 40 mg Delayed-Release Tablets) of The Government Pharmaceutical Organization, Thailand with CONTROLOC (Pantoprazole 40 mg Gastro-resistant Tablets) of Takeda GmbH, Germany, in Normal, Healthy, Adults Human Subjects under Fed Conditions